Core Viewpoint - ImmuCell Corporation reported significant growth in product sales and improved financial performance for the year ended December 31, 2024, indicating a recovery from previous contamination issues and a focus on enhancing production yields and gross margins [2][5][6]. Financial Performance - Product sales for Q4 2024 increased by 52% to approximately $7.8 million compared to $5.1 million in Q4 2023 [5][6]. - For the full year 2024, product sales also rose by 52% to approximately $26.5 million, up from $17.5 million in 2023 [5][6]. - Gross margin improved to 37% in Q4 2024 from 25% in Q4 2023, and for the full year, it increased to 30% from 22% [6]. - Net income for Q4 2024 was $515,000, or $0.06 per diluted share, compared to a net loss of $1,140,000, or ($0.15) per share in Q4 2023 [6][11]. - The company achieved positive EBITDA of approximately $1,331,000 in Q4 2024, contrasting with negative EBITDA of approximately ($311,000) in Q4 2023 [6][15]. Balance Sheet Highlights - Cash and cash equivalents rose to $3.8 million as of December 31, 2024, from $979,000 a year earlier [10][13]. - Net working capital increased to approximately $10.6 million from $7.3 million [10][13]. - Stockholders' equity grew to $27.5 million from $25 million [10][13]. Product Development and Regulatory Updates - The company is working towards FDA approval for Re-Tain, with a Controlled Launch pending FDA clearance of inspectional observations [2][6]. - Discussions with the FDA are ongoing to expedite the review process for the product [2]. Company Overview - ImmuCell Corporation focuses on developing and marketing products that enhance the health and productivity of dairy and beef cattle, including its First Defense product line and the upcoming Re-Tain treatment [17].

Company Overview - ImmuCell Corporation is an animal health company focused on developing, manufacturing, and marketing products that enhance the health and productivity of dairy and beef cattle [5] - The company is known for its product First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a treatment for subclinical mastitis in dairy cows [5] Financial Reporting - ImmuCell expects to report unaudited financial results for the quarter and year ended December 31, 2024, after the market closes on February 25, 2025 [1] - The company anticipates no change to the preliminary sales results for the fourth quarter and year ended December 31, 2024, which were disclosed on January 9, 2025 [3] - An Annual Report on Form 10-K is expected to be filed on or before March 31, 2025 [3] Conference Call - A conference call to review the unaudited financial results is scheduled for February 26, 2025, at 9:00 AM ET [2] - Interested parties can access the call via specific toll-free and international numbers, with a replay available until March 5, 2025 [2] Investor Relations - Investors are encouraged to review the updated Corporate Presentation slide deck available on the company's website, which provides an overview of the business [4] - An updated version of the slide deck will be made available after the market closes on February 25, 2025 [4]

Core Points - ImmuCell Corporation is set to report unaudited financial results for the quarter and year ended December 31, 2024, after market close on February 25, 2025 [1] - A conference call to discuss these results is scheduled for February 26, 2025, at 9:00 AM ET [2] - The company anticipates no changes to the preliminary sales results disclosed on January 9, 2025 [3] - An updated Corporate Presentation slide deck will be available after market close on February 25, 2025, providing an overview of the company's business [4] - ImmuCell focuses on developing products that enhance the health and productivity of dairy and beef cattle, including First Defense and the novel treatment Re-Tain [5]

PORTLAND, Maine, Jan. 16, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has settled an insurance claim covering some of the losses incurred from production contamination events. The Company settled a long outstanding insurance claim related to previously dis ...

PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2024. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaud ...

PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2024. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaud ...

Zacks Investment Research has recently initiated the coverage of ImmuCell Corporation (ICCC) with a “Neutral” recommendation. The Portland, ME-based company, founded in 1982, specializes in scientifically proven animal health products aimed at improving the health and productivity of dairy and beef cattle. This balanced outlook reflects the company's potential and the risks inherent in its operations and market environment.ImmuCell's market-leading First Defense product line stands out in the $75-million sc ...

Core Viewpoint - ImmuCell Corporation is set to report its unaudited financial results for Q3 2024 on November 13, 2024, and will host a conference call the following day to discuss these results [1][2][3]. Financial Reporting - The company anticipates no changes to the preliminary sales results for Q3 2024, which were previously disclosed on October 8, 2024 [3]. - The Quarterly Report on Form 10-Q will be filed after market close on November 13, 2024 [3]. Conference Call Details - A conference call to review the unaudited financial results will take place on November 14, 2024, at 9:00 AM ET, accessible via specific dialing options [2]. - A teleconference replay will be available until November 21, 2024, with a designated access code [2]. Corporate Presentation - Investors are encouraged to review the updated Corporate Presentation slide deck available on the company's website, which will be updated after the financial results are released [4]. Company Overview - ImmuCell Corporation focuses on developing products that enhance the health and productivity of dairy and beef cattle, including First Defense® for newborn calves and Re-Tain®, a treatment for subclinical mastitis [5].

PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-M ...

Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024 For Immediate Release PORTLAND, Maine – August 13, 2024 – ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2024. Q2 2024 Highl ...